MHTX — Manhattan Scientifics Income Statement
0.000.00%
- $0.06m
- $1.14m
Annual income statement for Manhattan Scientifics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.097 | 0.05 | 0.05 | 0.05 | 0 |
Cost of Revenue | |||||
Gross Profit | 0.097 | — | — | — | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.12 | 0.725 | 0.737 | 0.729 | 0.688 |
Operating Profit | -1.02 | -0.675 | -0.687 | -0.679 | -0.688 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1.22 | 4.31 | -3.64 | -2.73 | -1.17 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1.22 | 4.31 | -3.64 | -2.73 | -1.17 |
Net Income Before Extraordinary Items | |||||
Net Income | -1.22 | 4.31 | -3.64 | -2.73 | -1.17 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1.22 | 4.31 | -3.64 | -2.73 | -1.17 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.002 | 0.007 | -0.007 | -0.005 | -0.002 |